Lexicon Pharmaceuticals | LXRX - Net Income


Lexicon Pharmaceuticals reported $-53.43M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
Abbott USD 1.78B 132M Dec/2025
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Coherus Biosciences USD -56.57M 5.87M Mar/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Illumina USD 334M 184M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
J&J USD 5.12B 36M Dec/2025
Lexicon Pharmaceuticals USD -53.43M 5.03M Jun/2024
MacroGenics USD 16.82M 53.07M Sep/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Novartis USD 3.93B 96M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Thermo Fisher Scientific USD 1.96B 348M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024